RU2008130413A - Фармацевтическая композиция для лечения геморрагического шока и его последствий - Google Patents
Фармацевтическая композиция для лечения геморрагического шока и его последствий Download PDFInfo
- Publication number
- RU2008130413A RU2008130413A RU2008130413/15A RU2008130413A RU2008130413A RU 2008130413 A RU2008130413 A RU 2008130413A RU 2008130413/15 A RU2008130413/15 A RU 2008130413/15A RU 2008130413 A RU2008130413 A RU 2008130413A RU 2008130413 A RU2008130413 A RU 2008130413A
- Authority
- RU
- Russia
- Prior art keywords
- pro
- arg
- gly
- peptide
- glu
- Prior art date
Links
- 208000032456 Hemorrhagic Shock Diseases 0.000 title claims abstract 4
- 206010049771 Shock haemorrhagic Diseases 0.000 title claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 9
- 102000009123 Fibrin Human genes 0.000 claims abstract 5
- 108010073385 Fibrin Proteins 0.000 claims abstract 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract 5
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract 5
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract 5
- 229950003499 fibrin Drugs 0.000 claims abstract 5
- 229940100601 interleukin-6 Drugs 0.000 claims abstract 5
- 230000004071 biological effect Effects 0.000 claims abstract 3
- 230000001939 inductive effect Effects 0.000 claims abstract 3
- 230000035939 shock Effects 0.000 claims abstract 3
- 210000002889 endothelial cell Anatomy 0.000 claims abstract 2
- 239000012634 fragment Substances 0.000 claims abstract 2
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 230000005764 inhibitory process Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010003497 Asphyxia Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 102000008790 VE-cadherin Human genes 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 230000036770 blood supply Effects 0.000 claims 1
- 108010018828 cadherin 5 Proteins 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 102000000905 Cadherin Human genes 0.000 abstract 2
- 108050007957 Cadherin Proteins 0.000 abstract 2
- 230000003511 endothelial effect Effects 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001553 hepatotropic effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0206705A AT502987A1 (de) | 2005-12-23 | 2005-12-23 | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
| ATA2067/2005 | 2005-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008130413A true RU2008130413A (ru) | 2010-01-27 |
Family
ID=37846035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008130413/15A RU2008130413A (ru) | 2005-12-23 | 2006-11-10 | Фармацевтическая композиция для лечения геморрагического шока и его последствий |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7897574B2 (https=) |
| EP (2) | EP1962887B1 (https=) |
| JP (1) | JP2009520696A (https=) |
| KR (1) | KR20080108221A (https=) |
| CN (1) | CN101365477A (https=) |
| AT (2) | AT502987A1 (https=) |
| AU (1) | AU2006326890A1 (https=) |
| CA (1) | CA2634026A1 (https=) |
| DE (1) | DE502006004619D1 (https=) |
| ES (1) | ES2331970T3 (https=) |
| IL (1) | IL192349A0 (https=) |
| NO (1) | NO20083191L (https=) |
| RU (1) | RU2008130413A (https=) |
| WO (1) | WO2007070899A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2641908A1 (en) * | 2006-02-23 | 2007-08-30 | Fibrex Medical Research & Development Gmbh | Peptides and peptide derivatives as well as pharmaceutical compositions containing the same |
| JP2010540892A (ja) * | 2007-09-24 | 2010-12-24 | ファイブレックス メディカル リサーチ アンド デベロップメント ゲーエムベーハー | 抗炎症活性を有する化合物をスクリーニングする方法 |
| US20130324469A1 (en) * | 2010-12-09 | 2013-12-05 | The Brigham And Women's Hospital, Inc. | Fibrinogen and kidney damage |
| TW201718028A (zh) * | 2015-10-13 | 2017-06-01 | 賽米克Ｉｐ有限責任公司 | Ve-鈣黏蛋白結合性生物結合物 |
| JP7506364B2 (ja) * | 2019-10-24 | 2024-06-26 | 国立大学法人東海国立大学機構 | 慢性肺疾患／急性呼吸窮迫症候群の治療薬 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997844A (en) | 1991-02-08 | 1999-12-07 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| BR0116122A (pt) | 2000-12-12 | 2003-10-14 | Fibrex Medical Res & Dev Gmbh | Peptìdeos e/ou proteìnas bem como seu uso para preparar uma composição farmacêutica, terapêutica e/ou preventiva |
| US20080311103A1 (en) * | 2004-03-08 | 2008-12-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Anti-Inflammatory Peptides and Methods of Use Thereof |
| AT414097B (de) | 2004-06-25 | 2006-09-15 | Petzelbauer Peter Dr | Pharmazeutische zubereitung zur behandlung von schock |
| DK1691827T3 (da) * | 2004-06-25 | 2009-12-14 | Fibrex Medical Res & Dev Gmbh | Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock |
-
2005
- 2005-12-23 AT AT0206705A patent/AT502987A1/de not_active Application Discontinuation
-
2006
- 2006-11-10 CN CNA2006800486507A patent/CN101365477A/zh active Pending
- 2006-11-10 RU RU2008130413/15A patent/RU2008130413A/ru not_active Application Discontinuation
- 2006-11-10 CA CA002634026A patent/CA2634026A1/en not_active Abandoned
- 2006-11-10 DE DE502006004619T patent/DE502006004619D1/de active Active
- 2006-11-10 ES ES06804388T patent/ES2331970T3/es active Active
- 2006-11-10 JP JP2008546020A patent/JP2009520696A/ja active Pending
- 2006-11-10 EP EP06804388A patent/EP1962887B1/de active Active
- 2006-11-10 AU AU2006326890A patent/AU2006326890A1/en not_active Abandoned
- 2006-11-10 EP EP09010282A patent/EP2110136A3/de not_active Withdrawn
- 2006-11-10 WO PCT/AT2006/000465 patent/WO2007070899A2/de not_active Ceased
- 2006-11-10 US US12/158,670 patent/US7897574B2/en not_active Expired - Fee Related
- 2006-11-10 KR KR1020087017988A patent/KR20080108221A/ko not_active Ceased
- 2006-11-10 AT AT06804388T patent/ATE440282T1/de active
-
2008
- 2008-06-19 IL IL192349A patent/IL192349A0/en unknown
- 2008-07-17 NO NO20083191A patent/NO20083191L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE440282T1 (de) | 2009-09-15 |
| KR20080108221A (ko) | 2008-12-12 |
| NO20083191L (no) | 2008-09-16 |
| CN101365477A (zh) | 2009-02-11 |
| AU2006326890A1 (en) | 2007-06-28 |
| EP1962887A2 (de) | 2008-09-03 |
| EP2110136A2 (de) | 2009-10-21 |
| US20090005310A1 (en) | 2009-01-01 |
| JP2009520696A (ja) | 2009-05-28 |
| EP2110136A3 (de) | 2010-01-27 |
| DE502006004619D1 (de) | 2009-10-01 |
| EP1962887B1 (de) | 2009-08-19 |
| ES2331970T3 (es) | 2010-01-21 |
| WO2007070899A3 (de) | 2007-10-04 |
| AT502987A1 (de) | 2007-07-15 |
| CA2634026A1 (en) | 2007-06-28 |
| US7897574B2 (en) | 2011-03-01 |
| WO2007070899A2 (de) | 2007-06-28 |
| IL192349A0 (en) | 2008-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jia et al. | Mechanical stretch‐induced endoplasmic reticulum stress, apoptosis and inflammation contribute to thoracic aortic aneurysm and dissection | |
| Borensztajn et al. | Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation | |
| Nijveldt et al. | The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis | |
| Bige et al. | Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction | |
| Yoshiya et al. | Blockade of the apelin–APJ system promotes mouse liver regeneration by activating Kupffer cells after partial hepatectomy | |
| Li et al. | Cardiac proteasome functional insufficiency plays a pathogenic role in diabetic cardiomyopathy | |
| Nergui et al. | Role of endothelial nitric oxide synthase and collagen metabolism in right ventricular remodeling due to pulmonary hypertension | |
| Lee et al. | DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury | |
| Farberov et al. | Functions and transcriptional regulation of thrombospondins and their interrelationship with fibroblast growth factor-2 in bovine luteal cells | |
| Ren et al. | AEBP1 promotes the occurrence and development of abdominal aortic aneurysm by modulating inflammation via the NF-κB pathway | |
| Zhang et al. | Up-regulation of components of the renin–angiotensin system in liver fibrosis in the rat induced by CCL4 | |
| NO20083191L (no) | Farmasoytisk sammensetning for behandling av hemoragisk sjokk og dens etterfolgende symptomer | |
| Vila Cuenca et al. | Differences in peritoneal response after exposure to low-GDP bicarbonate/lactate-buffered dialysis solution compared to conventional dialysis solution in a uremic mouse model | |
| Chi et al. | Knockdown of myeloid differentiation protein-2 reduces acute lung injury following orthotopic autologous liver transplantation in a rat model | |
| Fakih et al. | Activated factor X stimulates atrial endothelial cells and tissues to promote remodelling responses through AT1R/NADPH oxidases/SGLT1/2 | |
| Iacobazzi et al. | Accelerated cardiac aging in patients with congenital heart disease | |
| Okada et al. | A possible anti-inflammatory role of angiotensin II type 2 receptor in immune-mediated glomerulonephritis during type 1 receptor blockade | |
| DE502006006466D1 (de) | Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen | |
| Hu et al. | Fasudil prevents calcium oxalate crystal deposit and renal fibrogenesis in glyoxylate-induced nephrolithic mice | |
| Nowińska et al. | Changes in pancreas caused by different types of hypertension | |
| Dai et al. | Ruscogenin alleviates deep venous thrombosis and pulmonary embolism induced by inferior vena cava stenosis inhibiting MEK/ERK/Egr-1/TF signaling pathway in mice | |
| Pomilio et al. | Endothelial dysfunction in children with type 1 diabetes mellitus. | |
| Zheng et al. | Mineralocorticoid receptor negatively regulates angiogenesis through repression of STAT3 activity in endothelial cells | |
| Wang et al. | Serum neutrophil gelatinase-associated lipocalin and proinflammatory cytokines in pigs with septic versus non-septic acute kidney injury | |
| JP2009520696A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110815 |